Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25188324 | 1.00 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL715096 | 1.00 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL30434262 | 1.00 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL30503037 | 1.00 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL29350327 | 1.00 | TAAR1 (0.72) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL35210364 | 0.98 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL30448521 | 0.98 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL25314458 | 0.98 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Hydrochloric Acid SCHEMBL5301741 | 0.98 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL29633088 | 0.88 | TAAR1 (0.68) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4433466-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-09-25 | — | — | EP | claimed |
| WO-2023092044-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3710837-B1 | CATHINONE TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2025-05-07 | — | — | EP | disclosed |
| US-20240409526-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC (US) | 2024-12-12 | — | — | US | disclosed |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | MINDSET PHARMA INC. (CA) | 2024-10-17 | — | — | US | disclosed |
| US-20240327371-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4433466-A2 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2024-09-25 | — | — | EP | disclosed |
| US-11958821-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | TERRAN BIOSCIENCES INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11808775-B2 | Cathinone test | UNIVERSITY OF TECHNOLOGY SYDNEY | 2023-11-07 | — | — | US | disclosed |
| US-20230227422-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES INC (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023081897-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081897-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | TERRAN BIOSCIENCES, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-8793078-B2 | Method for predicting activation energy using atomic fingerprint descriptor or atomic descriptor | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2014-07-29 | — | — | US | disclosed |
| US-20120084012-A1 | METHOD FOR PREDICTING ACTIVATION ENERGY USING ATOMIC FINGERPRINT DESCRIPTOR OR ATOMIC DESCRIPTOR | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2012-04-05 | — | — | US | disclosed |
| US-20110213558-A1 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | BIOINFORMATICS & MOLECULAR DESIGN RESEARCH CENTER (KR) | 2011-09-01 | — | — | US | disclosed |
| EP-2354987-A2 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | Bioinformatics&Molecular Design Research Center (KR) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010056053-A2 | METHOD FOR PREDICTING ACTIVATION ENERGY USING AN ATOMIC FINGERPRINT DESCRIPTOR OR AN ATOMIC DESCRIPTOR | 사단법인 분자설계연구소 (KR) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577222-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | DRD2, DRD1, DRD3 | TAAR1 81/4885SLC6A4 59/4885SLC6A2 17/4885 |
| US-20240409526-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | DRD2, DRD3, DRD1 | TAAR1 133/4885SLC6A4 16/4885SLC6A2 11/4885 |
| US-20240342126-A1 | HALLUCINOGEN-FATTY ACID COMBINATION | FAAH, HTR5A, FAAH2 | TAAR1 47/4885SLC6A4 44/4885SLC6A2 58/4885 |
| US-20230150966-A1 | ISOTOPICALLY ENRICHED 3,4-METHYLENEDIOXY-N-ETHYLAMPHETAMINE (MDE) AND STEREOISOMERS THEREOF | SLC6A3, DBH, PNMT | TAAR1 103/4885SLC6A4 12/4885SLC6A2 10/4885 |
| US-20240327371-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | DRD2, DRD3, DRD1 | TAAR1 133/4885SLC6A4 16/4885SLC6A2 11/4885 |
| US-20230227422-A1 | PHENETHYLAMINE COMPOUNDS SALTS, POLYMORPHIC FORMS AND METHODS OF USE THEREOF | DRD2, DRD3, DRD1 | TAAR1 133/4885SLC6A4 16/4885SLC6A2 11/4885 |
| US-11958821-B2 | Phenethylamine compounds salts, polymorphic forms and methods of use thereof | DRD2, DRD3, DRD1 | TAAR1 133/4885SLC6A4 16/4885SLC6A2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.